Detailed Results From SUPPRESS Trial of Brincidofovir to be Presented at BMT Tandem Meetings

DURHAM, N.C., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that detailed results from the Company’s Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT), will be presented at the BMT Tandem Meetings in Honolulu, Hawaii. The presentation will be held on Saturday, February 20, 2016 at 4:00 p.m. HST (9:00 p.m. EST) at the Hawaii Convention Center in Honolulu, Hawaii. Presentation slides will be posted to the Chimerix website following the conclusion of the presentation.

Chimerix’s management team will host a live conference call and webcast at 8:00 a.m. EST on Monday, February 22, 2016 to discuss the SUPPRESS trial results as well as provide an update on the brincidofovir clinical program. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 52881232.

A live webcast of the call and accompanying slides will also be available on the Investors’ section of the Company’s website, and an archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. For further information, please visit Chimerix's website,

CONTACT: Investor Relations: or Jesse Baumgartner Stern Investor Relations 212-362-1200 Media: Becky Vonsiatsky W2O Group 413-478-2003

Source:Chimerix, Inc.